We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
SIGMA ALDRICH CORP.

BIOVENDOR

BioVendor Instruments a.s. is involved in research & development related to automation and optimization of processes ... read more Featured Products: More products

BioVendor Acquires All Shares of DIAsource ImmunoAssays SA

By Labmedica International staff writers
Posted on 16 Oct 2017
Print article
Image: BioVendor has acquired 100% of the shares of DIAsourceImmunoAssays SA (Photo courtesy of iStock).
Image: BioVendor has acquired 100% of the shares of DIAsourceImmunoAssays SA (Photo courtesy of iStock).
BioVendor - Laboratornímedicínaa.s. (Brno, Czech Republic), an international diagnostics holding, has acquired 100% of the shares of DIAsourceImmunoAssays SA (Louvain-La-Neuve, Belgium) from Anteo Diagnostics (Queensland, Australia), which had acquired DIAsource in January 2016.

DIAsource specializes in the development, in manufacturing, sales and distribution of immunoassay tests and open instrumentation solutions for clinical medical diagnostics. The company is a leading provider in IVD market segments such as Vitamin D, ELISA and RIA assays, with its clinical diagnostics product catalog featuring over 190 ELISA and 140 RIA assays.

The acquisition of DIAsource has extended BioVendor’s broad panel of ELISA and RIA assays, antibodies and reagents for clinical diagnostics, as well as established a direct sales presence in Belgium, France and Spain, and a worldwide network of over 100 sales and distribution partners in over 70 countries. DIAsource represents BioVendor’s largest acquisition to date and follows previous acquisitions carried out since 2014 in line with its long-term plan of international expansion.


Print article

Channels

Copyright © 2000-2018 Globetech Media. All rights reserved.